<DOC>
	<DOCNO>NCT00121641</DOCNO>
	<brief_summary>The purpose clinical research study learn whether saxagliptin ( BMS-477118 ) effective placebo treatment type 2 diabetic subject sufficiently control diet exercise</brief_summary>
	<brief_title>Saxagliptin Treatment Subjects With Type 2 Diabetes Who Are Not Controlled With Diet Exercise</brief_title>
	<detailed_description>All subject participate lead-in period , qualify subject continue short-term randomized treatment period . Subjects complete short-term period eligible enter long term extension period . Also , subject short-term period elevate blood sugar require additional medication blood sugar control eligible enter long-term treatment extension period receive metformin add onto blind study medication . Subjects screen hemoglobin A1c ( A1C ) &gt; 10.0 % â‰¤ 12.0 % , otherwise meet inclusion/exclusion criterion , eligible enroll directly Open-Label Treatment Cohort ( Direct Enrollees ) receive open-label saxagliptin 10 mg. Those complete short-term period eligible enter long-term treatment extension period.Saxagliptin dose titration permit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus Drug naive Hemoglobin ( Hb ) A1c &gt; = 7.0 % &lt; = 10.0 % ( &gt; 10 % &lt; = 12 % open label arm ) Fasting Cpeptide &gt; = 1 ng/mL Body mass index &lt; = 40 kg/m2 Symptomatic poorly control diabetes Recent cardiac cerebrovascular event Serum creatinine &gt; = 1.5 mg/dL male &gt; = 1.4 mg/dL Women Child Bearing Potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>